OncoMatch/Clinical Trials/NCT04510636
Study of Pembrolizumab With Bendamustine in Hodgkin Lymphoma
Is NCT04510636 recruiting? Yes, currently enrolling (Jul 2026). This Phase 2 trial studies multiple treatments including Pembrolizumab and Bendamustine Hydrochloride for classical hodgkin lymphoma.
Treatment: Pembrolizumab · Bendamustine Hydrochloride — This is a phase 2 open-label study to test the safety and effectiveness of combining pembrolizumab and bendamustine in patients with relapsed (cancer that has come back or started getting worse) or refractory (cancer that is not responding or has stopped responding to treatment) Hodgkin lymphoma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Chemotherapy
Cancer type
Hodgkin Lymphoma
Tumor Agnostic
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: anthracycline-containing chemotherapy (abvd, beacopp) — first line for classical hodgkin lymphoma
Cannot have received: bendamustine (bendamustine)
Cannot have received: allogeneic hematopoietic stem cell transplant
Cannot have received: checkpoint inhibitor (pembrolizumab, anti-pd1, anti-pd-l1, anti-pd-l2, anti-cd137, anti-ctla-4, anti-ox-40)
Exception: unless patient did not progress on therapy and/or received intervening systemic therapy after checkpoint inhibitor
Lab requirements
Blood counts
demonstrate adequate organ and bone marrow function. all screening laboratory tests should be performed within 7 days of treatment initiation.
Kidney function
demonstrate adequate organ and bone marrow function. all screening laboratory tests should be performed within 7 days of treatment initiation.
Liver function
demonstrate adequate organ and bone marrow function. all screening laboratory tests should be performed within 7 days of treatment initiation.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT04510636 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior bendamustine, allogeneic hematopoietic stem cell transplant, checkpoint inhibitor disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages